ClinicalTrials.gg
CompletedNCT01473407AiME - 01Updated Sep 10, 2018Results posted

A Phase 3 Study Comparing the Effects of Intravenous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

A Phase 3 interventional study of Epoetin Hospira and Epogen (Amgen) in Chronic Kidney Disease and Chronic Renal Failure, sponsored by Pfizer. Completed at 85 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-09-10.

Primary conditionKidney Failure, ChronicRegistry: Renal Insufficiency, ChronicReclassifiedWhy we changed it
Registry
Renal Insufficiency, Chronic — the first condition term the registry derived for this study.
ClinicalTrials.gg
Kidney Failure, Chronic
Why
  1. The study's listed conditions name Kidney Failure, Chronic, a narrower term within Renal Insufficiency, Chronic.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
612
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing Epoetin Alfa in Kidney Failure, Chronic — none open to participants now, none under way, none of them phase 3. Epoetin Alfa · Kidney Failure, Chronic.

Enrollment
2nd of 13
612 · median 292
Started
2012
with 4 others
Phase 3
5 of 13
none open now
Registered
9th of 13
by date
Lead sponsor
4 of 13
Pfizer

Among the 13 studies testing Epoetin Alfa in Kidney Failure, Chronic, this one is the 2nd largest by enrollment, is one of 5 that started in 2012, is one of 5 in phase 3, and was the 9th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

None of the 13 studies testing Epoetin Alfa in Kidney Failure, Chronic is open now. The open studies under Kidney Failure, Chronic, anywhere →

Where they have run

About Epoetin Alfa

Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing Epoetin Alfa in Kidney Failure, Chronic as a file.
02

Study summary

The purpose of this study is to demonstrate therapeutic equivalence of IV Epoetin Hospira compared to IV Epogen (Amgen), based on maintenance of Hb levels and study drug dose requirements in patients treated for anemia associated with chronic renal failure and on hemodialysis.

03

Conditions studied

  • Chronic Kidney Disease
  • Chronic Renal Failure

Browse trials for

04

In context

Kidney Failure, Chronic Reclassified

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

This study's enrollment of 612 is above the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.

Browse Kidney Failure, Chronic studies →

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Compared within Kidney Failure, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Renal Insufficiency, Chronic. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient is able to provide written after risks and benefits of the study have been explained prior to any study related activities
  2. Hemodialysis patients with chronic renal failure and renal anemia currently on stable Epogen (Amgen) treatment for at least 4 weeks prior to randomization, for whom the following apply (during this period):

    • Epogen (Amgen) dose has been administered intravenously 1 to 3 times per week with no more than a 10% dose change from the mean for at least 4 weeks prior to randomization
    • Stable , defined as meeting all of the following:

      • Mean hemoglobin during the 4 weeks prior to randomization between 9.0 and 11.0 g/dL
      • No more than one hemoglobin outside of range from 9.0-11.0 g/dL during the 4 weeks prior to randomization
      • No hemoglobin result more than ±1 g/dL from the mean hemoglobin level during the 4 week period prior to randomization
  3. Patients on stable, adequate dialysis for at least 12 weeks prior to randomization, defined as no changes of dialysis regimen and/or dialyzer
  4. Patients with adequate iron stores, defined as ferritin >100 μg/L and TSAT >20%, prior to randomization
  5. Male or female patients aged 18 to 80 years (both inclusive)
  6. If female, patient must be either for at least 1 year prior to randomization, surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), or practicing at least 1 of the following methods of :

    • hormonal contraceptives (oral, parenteral, or transdermal) for at least 3 months prior to randomization
    • intrauterine device (IUD)
    • double-barrier method (condoms, contraceptive sponge, diaphragm, or vaginal ring with spermicidal jellies or cream)

If hormonal contraceptives are used, the specific contraceptive must have been used for at least 3 months prior to randomization. If the patient is currently using a hormonal contraceptive, she should also use a barrier method during this study and for at least 30 days following the administration of the patient's last dose

Exclusion criteria

Exclusion Criteria:

  1. Maintenance Epoetin dosage >600 U/kg per week (1-3 times per week)
  2. Treatment with long-acting epoetin analogues such as Aranesp ® within 3 months prior to randomization
  3. Any of the following within 3 months prior to randomization:

    • Myocardial infarction
    • Stroke (cerebrovascular accident)/cerebrovascular insult (minor stroke) or /intracerebral bleeding/cerebral infarction
    • Severe/unstable angina
    • Coronary angioplasty, bypass surgery, or peripheral artery bypass graft
    • Decompensated congestive heart failure ( [NYHA] class IV)
    • Pulmonary embolism
    • Deep vein thrombosis or other thromboembolic event
    • Received live or attenuated vaccination (except flu vaccination)
  4. Uncontrolled Hypertension within the 4 weeks prior to randomization, defined as more than 10% of post-dialysis blood pressures >170 mmHg systolic and/or >110 mmHg diastolic, based on blood pressure readings obtained when the patient's post-dialysis body weight was not more than 0.5 kg above their listed dry weight
  5. Known, clinically manifested deficiency of folic acid and/or vitamin B12 (irrespective of whether currently treated or not)
  6. A patient with any active, uncontrolled systemic, inflammatory or malignant disease (including demyelinating diseases such as multiple sclerosis) that in the Investigator's opinion may be significant to exclude participation in the study, including but not limited to microbial, viral, or fungal infection or mental disease
  7. for the test drug or have been previously treated with Epoetin Hospira
  8. Relative or absolute iron deficiency prior to randomization
  9. count below 100 x 10\^9/L
  10. increase of CRP (>10 mg/dL) for at least 2 weeks
  11. Significant drug sensitivity or a significant allergic reaction to any drug, as well as known or idiosyncratic reaction to epoetin (or its , including albumin) or any other related drugs that in the judgment of the Investigator is exclusionary for the study participation
  12. History of any of the following:

    • Detectable anti- rhEPO antibodies
    • Clinically relevant malnutrition
    • Confirmed aluminum intoxication
    • Myelodysplastic syndrome
    • Known bone marrow fibrosis (osteitis fibrosa cystica)
    • Known seizure disorder
    • Liver cirrhosis with clinical evidence of complications (portal hypertension, splenomegaly, ascites)
  13. A female patient who is pregnant, lactating or planning a pregnancy during the study
  14. History of drug abuse or alcohol abuse within 2 years prior to randomization as determined by the Investigator
  15. Current participation or participation in a drug or other research study within 30 days prior to randomization
  16. May not be able to comply with the requirements of this clinical study, communicate effectively with study personnel, or is considered by the Investigator, for any reason, to be an unsuitable candidate for the study
  17. Donated or lost >475 mL (i.e., 1 pint) blood volume (including plasmapheresis) or had a transfusion of any blood product within 3 months prior to randomization
  18. A patient who in the Investigator's opinion, has any clinically significant abnormal laboratory evaluations, including liver function taken at Screening Visit
  19. Positive laboratory test for (HIV) or surface antigen (HBsAg)
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
612 participants (actual)

Study arms

  • Experimental
    Epoetin Hospira

    Epoetin Hospira

    Biological: Epoetin Hospira

  • Active comparator
    Epogen (Amgen)

    Epogen (Amgen)

    Biological: Epogen (Amgen)

Interventions

07

What researchers measure

Primary outcomes

  1. Mean Weekly Hemoglobin Level From Week 21 to Week 24

    Time frame: Week 21 up to Week 24

  2. Mean Weekly Dosage of Study Medication From Week 21 to Week 24

    Time frame: Week 21 up to Week 24

Secondary outcomes

  1. Mean Weekly Hemoglobin Level Through 24 Weeks

    Time frame: Week 1 up to Week 24

  2. Mean Weekly Dosage of Study Medication Through 24 Weeks

    Time frame: Week 1 up to Week 24

  3. Total Dose of Study Medication Administered

    Time frame: Week 1 up to Week 24

  4. Percentage of Participants With Mean Weekly Hemoglobin Level Within the Target Range

    Percentage of participants who had hemoglobin level within the target range of 9 to 11 g/dL for the specified weeks were reported.

    Time frame: Week 12, 24

  5. Percentage of Participants Who Required Permanent Dose Changes of Study Medication

    Time frame: Week 1 up to Week 24

  6. Percentage of Participants Who Required Temporary Dose Changes of Study Medication

    Time frame: Week 1 up to Week 24

  7. Percentage of Participants With Any Transient Change of Hemoglobin Level Greater Than (>) 1 Gram Per Deciliter (g/dL)

    Time frame: Week 1 up to Week 24

  8. Percentage of Participants With Mean Weekly Hemoglobin Level Outside the Target Range

    Percentage of participants who had hemoglobin level outside the target range of 9 to 11 g/dL for the specified weeks were reported.

    Time frame: Week 12, 24

  9. Percentage of Participants Who Received Blood Transfusions

    Time frame: Week 1 up to Week 24

  10. Number of Participants With Change in Mean Dose of Study Medication Based on Hemoglobin Level

    In this outcome measure number of participants with change (increase and decrease) in mean dose of Epoetin Hospira and Epogen were categorized and reported according to their mean hemoglobin levels. Hemoglobin levels were divided in following classes: \>11.0 g/dL, from 9.0 to 11.0 g/dL and \<9.0 g/dL

    Time frame: Week 1 up to Week 24

  11. Percentage of Participants With Any Transient Change of Hemoglobin Greater Than (>) 2.0 Gram Per Deciliter (g/dL) in Hemoglobin Level

    Time frame: Week 1 up to Week 24

Other outcomes

  1. Percentage of Participants With Hemoglobin Level Less Than (<) 8.0 Gram Per Deciliter (g/dL)

    Time frame: Week 1 up to Week 24

  2. Percentage of Participants With Hemoglobin Level Greater Than (>) 12.0 Gram Per Deciliter (g/dL)

    Time frame: Week 1 up to Week 24

  3. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; Initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events from first dose of study drug to the end of study (up to Week 28) that were absent before treatment or that worsened relative to pre-treatment state. AEs included both serious and non-serious adverse events.

    Time frame: Week 1 up to Week 28

  4. Number of Participants With Treatment-Emergent Adverse Events by Severity

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent were events between first dose of study drug to the end of study (up to Week 28) that were absent before treatment or that worsened relative to pre-treatment state. An AE was assessed according to severity; mild (AE was transient and easily tolerated by the participant), moderate (caused problem that did not interfere significantly with usual activities) and severe (caused problem that interferes significantly with usual activities and might be incapacitating or life-threatening).

    Time frame: Week 1 up to Week 28

  5. Number of Participants With Treatment Related Adverse Events (AEs)

    An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug.

    Time frame: Week 1 up to Week 28

  6. Number of Participants That Discontinued Treatment Due to a Treatment Emergent Adverse Event

    In this outcome measure number of participants who discontinued from study drug (Epoetin Hospira, Epogen) due to any AE were reported.

    Time frame: Week 1 up to Week 28

  7. Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters

    Laboratory parameters: Hematology (hematocrit, hemoglobin, red blood cell count, reticulocytes, white blood cell count, neutrophils, bands, lymphocytes, monocytes, basophils, eosinophils, platelet count, mean corpuscular volume); coagulation panel (prothrombin time, international normalized ratio, activated partial thromboplastin time); clinical chemistry (blood urea nitrogen, creatinine, alanine aminotransferase, aspartate aminotransferase, total bilirubin, gamma-glutamyl transpeptidase, alkaline phosphatase, sodium, potassium, calcium, magnesium, phosphorus, uric acid, total protein, glucose, albumin, C-reactive protein, plasma ferritin, transferrin saturation). Participants with clinically significant change from baseline in laboratory parameters were as determined by the investigator.

    Time frame: Baseline up to Week 28

  8. Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Vital sign parameters: temperature (oral, tympanic, or other), blood pressure (diastolic and systolic), heart rate (in a seated position) and dry weight (post-dialysis). Participants with clinically significant change from baseline in vital signs were as determined by the investigator.

    Time frame: Baseline up to Week 28

  9. Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG)

    ECG parameters: PR interval, QRS complex, QT interval and QTC interval. Participants with clinically significant change from baseline in ECG were as determined by the investigator.

    Time frame: Baseline up to Week 28

  10. Number of Participants With Clinically Significant Change From Baseline in Physical Examination

    Physical examination included examination of the following: skin, eyes, ears, throat, cardiac, respiratory, gastrointestinal, genitourinary and musculoskeletal systems. Participants with clinically significant change from baseline in physical examination were as determined by the investigator.

    Time frame: Baseline up to Week 28

  11. Percentage of Participants With Anti-Recombinant Human Erythropoietin (Anti-rhEPO) Antibodies

    Percentage of participants with presence of anti-rhEPO antibodies were reported in this outcome measure. Radioimmunoprecipitation assay method was used to determine the presence of anti-rhEPO antibodies.

    Time frame: Week 1 up to Week 28

08

Results

Posted Jul 13, 2018

Participant flow

Participants with chronic renal failure were receiving Epoetin maintenance therapy prior to enrollment and treatment in this study.

Participant flow — Overall Study
MilestoneEpoetin HospiraEpogen
Started306306
Completed252259
Not completed5447
Withdrew: Physician decision14
Withdrew: Lost to follow-up104
Withdrew: Adverse event88
Withdrew: Randomization error31
Withdrew: Withdrawal by subject47
Withdrew: Kidney transplant76
Withdrew: Vacation/travel11
Withdrew: Elevated hemoglobin10
Withdrew: Patient received aranesp10
Withdrew: Patient lost green card status10
Withdrew: Temperature excursion23
Withdrew: Transfer to another facility/unit43
Withdrew: Sponsor's decision1010
Withdrew: Site closure10

Outcome measures

PrimaryMean Weekly Hemoglobin Level From Week 21 to Week 24
Time frame:
Week 21 up to Week 24
Reported as:
Mean · g/dL
Mean Weekly Hemoglobin Level From Week 21 to Week 24
g/dLEpoetin HospiraEpogen
Mean Weekly Hemoglobin Level From Week 21 to Week 2410.17 ± 0.84710.28 ± 0.839
Statistical analysis
  • Epoetin Hospira vs Epogen · Ls mean difference: -0.12 · 95% CI -0.25 to 0.01
PrimaryMean Weekly Dosage of Study Medication From Week 21 to Week 24
Time frame:
Week 21 up to Week 24
Reported as:
Mean · unit per kilogram per week (U/kg/week)
Mean Weekly Dosage of Study Medication From Week 21 to Week 24
unit per kilogram per week (U/kg/week)Epoetin HospiraEpogen
Mean Weekly Dosage of Study Medication From Week 21 to Week 2489.61 ± 99.82490.37 ± 88.492
Statistical analysis
  • Epoetin Hospira vs Epogen · Ls mean difference: 0.37 · 95% CI -10.40 to 11.13
SecondaryMean Weekly Hemoglobin Level Through 24 Weeks
Time frame:
Week 1 up to Week 24
Reported as:
Mean · g/dL
Mean Weekly Hemoglobin Level Through 24 Weeks
g/dLEpoetin HospiraEpogen
Mean Weekly Hemoglobin Level Through 24 Weeks10.25 ± 0.59110.26 ± 0.597
Statistical analysis
  • Epoetin Hospira vs Epogen · Wilcoxon Rank Sum test · p = 0.7563 (P-value was calculated from a Wilcoxon Rank Sum test and t-approximation was used.)
SecondaryMean Weekly Dosage of Study Medication Through 24 Weeks
Time frame:
Week 1 up to Week 24
Reported as:
Mean · U/kg/week
Mean Weekly Dosage of Study Medication Through 24 Weeks
U/kg/weekEpoetin HospiraEpogen
Mean Weekly Dosage of Study Medication Through 24 Weeks87.51 ± 86.40590.95 ± 80.619
Statistical analysis
  • Epoetin Hospira vs Epogen · Wilcoxon Rank Sum test · p = 0.1061 (P-value was calculated from a Wilcoxon Rank Sum test and t-approximation was used.)
SecondaryTotal Dose of Study Medication Administered
Time frame:
Week 1 up to Week 24
Reported as:
Mean · units of study medication
Total Dose of Study Medication Administered
units of study medicationEpoetin HospiraEpogen
Total Dose of Study Medication Administered146752.6 ± 156128.97147145.2 ± 141911.73
Statistical analysis
  • Epoetin Hospira vs Epogen · Wilcoxon Rank Sum test · p = 0.3369 (P-value was calculated from a Wilcoxon Rank Sum test and t-approximation was used.)
SecondaryPercentage of Participants With Mean Weekly Hemoglobin Level Within the Target Range

Percentage of participants who had hemoglobin level within the target range of 9 to 11 g/dL for the specified weeks were reported.

Time frame:
Week 12, 24
Reported as:
Number · percentage of participants
Percentage of Participants With Mean Weekly Hemoglobin Level Within the Target Range
percentage of participantsEpoetin HospiraEpogen
Week 1281.0 ± 156128.9773.2 ± 141911.73
Week 2473.271.4
SecondaryPercentage of Participants Who Required Permanent Dose Changes of Study Medication
Time frame:
Week 1 up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Required Permanent Dose Changes of Study Medication
percentage of participantsEpoetin HospiraEpogen
Percentage of Participants Who Required Permanent Dose Changes of Study Medication86.3 ± 156128.9793.2 ± 141911.73
SecondaryPercentage of Participants Who Required Temporary Dose Changes of Study Medication
Time frame:
Week 1 up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Required Temporary Dose Changes of Study Medication
percentage of participantsEpoetin HospiraEpogen
Percentage of Participants Who Required Temporary Dose Changes of Study Medication7.4 ± 156128.974.2 ± 141911.73
SecondaryPercentage of Participants With Any Transient Change of Hemoglobin Level Greater Than (>) 1 Gram Per Deciliter (g/dL)
Time frame:
Week 1 up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Any Transient Change of Hemoglobin Level Greater Than (>) 1 Gram Per Deciliter (g/dL)
percentage of participantsEpoetin HospiraEpogen
Percentage of Participants With Any Transient Change of Hemoglobin Level Greater Than (>) 1 Gram Per Deciliter (g/dL)44.1 ± 156128.9743.2 ± 141911.73
SecondaryPercentage of Participants With Mean Weekly Hemoglobin Level Outside the Target Range

Percentage of participants who had hemoglobin level outside the target range of 9 to 11 g/dL for the specified weeks were reported.

Time frame:
Week 12, 24
Reported as:
Number · percentage of participants
Percentage of Participants With Mean Weekly Hemoglobin Level Outside the Target Range
percentage of participantsEpoetin HospiraEpogen
Week 1219.026.8
Week 2426.828.6
SecondaryPercentage of Participants Who Received Blood Transfusions
Time frame:
Week 1 up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Received Blood Transfusions
percentage of participantsEpoetin HospiraEpogen
Percentage of Participants Who Received Blood Transfusions6.3 ± 156128.975.9 ± 141911.73
SecondaryNumber of Participants With Change in Mean Dose of Study Medication Based on Hemoglobin Level

In this outcome measure number of participants with change (increase and decrease) in mean dose of Epoetin Hospira and Epogen were categorized and reported according to their mean hemoglobin levels. Hemoglobin levels were divided in following classes: \>11.0 g/dL, from 9.0 to 11.0 g/dL and \<9.0 g/dL

Time frame:
Week 1 up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Change in Mean Dose of Study Medication Based on Hemoglobin Level
ParticipantsEpoetin HospiraEpogen
Dose Decrease: Hb <9.0 g/dL49 ± 156128.9737 ± 141911.73
Dose Decrease: Hb (9 to 11 g/dL)4946
Dose Decrease: Hb >11.0 g/dL147150
Dose Increase: Hb <9.0 g/dL5067
Dose Increase: Hb (9 to 11 g/dL)2726
Dose Increase: Hb >11.0 g/dL3654
SecondaryPercentage of Participants With Any Transient Change of Hemoglobin Greater Than (>) 2.0 Gram Per Deciliter (g/dL) in Hemoglobin Level
Time frame:
Week 1 up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Any Transient Change of Hemoglobin Greater Than (>) 2.0 Gram Per Deciliter (g/dL) in Hemoglobin Level
percentage of participantsEpoetin HospiraEpogen
Percentage of Participants With Any Transient Change of Hemoglobin Greater Than (>) 2.0 Gram Per Deciliter (g/dL) in Hemoglobin Level13.1 ± 156128.9714.5 ± 141911.73
Other pre-specifiedPercentage of Participants With Hemoglobin Level Less Than (<) 8.0 Gram Per Deciliter (g/dL)
Time frame:
Week 1 up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Hemoglobin Level Less Than (<) 8.0 Gram Per Deciliter (g/dL)
percentage of participantsEpoetin HospiraEpogen
Percentage of Participants With Hemoglobin Level Less Than (<) 8.0 Gram Per Deciliter (g/dL)5.3 ± 156128.9710.9 ± 141911.73
Other pre-specifiedPercentage of Participants With Hemoglobin Level Greater Than (>) 12.0 Gram Per Deciliter (g/dL)
Time frame:
Week 1 up to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Hemoglobin Level Greater Than (>) 12.0 Gram Per Deciliter (g/dL)
percentage of participantsEpoetin HospiraEpogen
Percentage of Participants With Hemoglobin Level Greater Than (>) 12.0 Gram Per Deciliter (g/dL)21.6 ± 156128.9723.0 ± 141911.73
Other pre-specifiedNumber of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; Initial or prolonged in-patient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events from first dose of study drug to the end of study (up to Week 28) that were absent before treatment or that worsened relative to pre-treatment state. AEs included both serious and non-serious adverse events.

Time frame:
Week 1 up to Week 28
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsEpoetin HospiraEpogen
AEs232 ± 156128.97229 ± 141911.73
SAEs7582
Other pre-specifiedNumber of Participants With Treatment-Emergent Adverse Events by Severity

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent were events between first dose of study drug to the end of study (up to Week 28) that were absent before treatment or that worsened relative to pre-treatment state. An AE was assessed according to severity; mild (AE was transient and easily tolerated by the participant), moderate (caused problem that did not interfere significantly with usual activities) and severe (caused problem that interferes significantly with usual activities and might be incapacitating or life-threatening).

Time frame:
Week 1 up to Week 28
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events by Severity
ParticipantsEpoetin HospiraEpogen
Mild116 ± 156128.97111 ± 141911.73
Moderate7469
Severe4249
Other pre-specifiedNumber of Participants With Treatment Related Adverse Events (AEs)

An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug.

Time frame:
Week 1 up to Week 28
Reported as:
Count of participants · Participants
Number of Participants With Treatment Related Adverse Events (AEs)
ParticipantsEpoetin HospiraEpogen
Number of Participants With Treatment Related Adverse Events (AEs)7 ± 156128.977 ± 141911.73
Other pre-specifiedNumber of Participants That Discontinued Treatment Due to a Treatment Emergent Adverse Event

In this outcome measure number of participants who discontinued from study drug (Epoetin Hospira, Epogen) due to any AE were reported.

Time frame:
Week 1 up to Week 28
Reported as:
Count of participants · Participants
Number of Participants That Discontinued Treatment Due to a Treatment Emergent Adverse Event
ParticipantsEpoetin HospiraEpogen
Number of Participants That Discontinued Treatment Due to a Treatment Emergent Adverse Event9 ± 156128.9711 ± 141911.73
Other pre-specifiedNumber of Participants With Clinically Significant Change From Baseline in Laboratory Parameters

Laboratory parameters: Hematology (hematocrit, hemoglobin, red blood cell count, reticulocytes, white blood cell count, neutrophils, bands, lymphocytes, monocytes, basophils, eosinophils, platelet count, mean corpuscular volume); coagulation panel (prothrombin time, international normalized ratio, activated partial thromboplastin time); clinical chemistry (blood urea nitrogen, creatinine, alanine aminotransferase, aspartate aminotransferase, total bilirubin, gamma-glutamyl transpeptidase, alkaline phosphatase, sodium, potassium, calcium, magnesium, phosphorus, uric acid, total protein, glucose, albumin, C-reactive protein, plasma ferritin, transferrin saturation). Participants with clinically significant change from baseline in laboratory parameters were as determined by the investigator.

Time frame:
Baseline up to Week 28
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters
ParticipantsEpoetin HospiraEpogen
Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters0 ± 156128.970 ± 141911.73
Other pre-specifiedNumber of Participants With Clinically Significant Change From Baseline in Vital Signs

Vital sign parameters: temperature (oral, tympanic, or other), blood pressure (diastolic and systolic), heart rate (in a seated position) and dry weight (post-dialysis). Participants with clinically significant change from baseline in vital signs were as determined by the investigator.

Time frame:
Baseline up to Week 28
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
ParticipantsEpoetin HospiraEpogen
Number of Participants With Clinically Significant Change From Baseline in Vital Signs0 ± 156128.970 ± 141911.73
Other pre-specifiedNumber of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG)

ECG parameters: PR interval, QRS complex, QT interval and QTC interval. Participants with clinically significant change from baseline in ECG were as determined by the investigator.

Time frame:
Baseline up to Week 28
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG)
ParticipantsEpoetin HospiraEpogen
Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG)0 ± 156128.970 ± 141911.73
Other pre-specifiedNumber of Participants With Clinically Significant Change From Baseline in Physical Examination

Physical examination included examination of the following: skin, eyes, ears, throat, cardiac, respiratory, gastrointestinal, genitourinary and musculoskeletal systems. Participants with clinically significant change from baseline in physical examination were as determined by the investigator.

Time frame:
Baseline up to Week 28
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Physical Examination
ParticipantsEpoetin HospiraEpogen
Number of Participants With Clinically Significant Change From Baseline in Physical Examination0 ± 156128.970 ± 141911.73
Other pre-specifiedPercentage of Participants With Anti-Recombinant Human Erythropoietin (Anti-rhEPO) Antibodies

Percentage of participants with presence of anti-rhEPO antibodies were reported in this outcome measure. Radioimmunoprecipitation assay method was used to determine the presence of anti-rhEPO antibodies.

Time frame:
Week 1 up to Week 28
Reported as:
Number · percentage of participants
Percentage of Participants With Anti-Recombinant Human Erythropoietin (Anti-rhEPO) Antibodies
percentage of participantsEpoetin HospiraEpogen
Percentage of Participants With Anti-Recombinant Human Erythropoietin (Anti-rhEPO) Antibodies0.4 ± 156128.970.0 ± 141911.73

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Epoetin Hospira—75/301 (24.9%)143/301 (47.5%)
Epogen—82/304 (27%)141/304 (46.4%)
Most frequent serious events
Showing 10 of 159
Most frequent serious events
EventEpoetin HospiraEpogen
PneumoniaInfections and infestations4/3018/304
DyspnoeaRespiratory, thoracic and mediastinal disorders3/3018/304
Non-cardiac chest painGeneral disorders2/3017/304
CellulitisInfections and infestations0/3016/304
Fluid overloadMetabolism and nutrition disorders1/3016/304
Cardiac failure congestiveCardiac disorders4/3013/304
Acute respiratory failureRespiratory, thoracic and mediastinal disorders4/3010/304
Angina pectorisCardiac disorders1/3014/304
HyperkalaemiaMetabolism and nutrition disorders2/3014/304
BradycardiaCardiac disorders3/3011/304
Most frequent other events
Showing 10 of 13
Most frequent other events
EventEpoetin HospiraEpogen
NauseaGastrointestinal disorders30/30125/304
VomitingGastrointestinal disorders28/30115/304
Muscle spasmsMusculoskeletal and connective tissue disorders27/30124/304
DiarrhoeaGastrointestinal disorders21/30127/304
Arteriovenous fistula site complicationInjury, poisoning and procedural complications25/30123/304
HeadacheNervous system disorders23/30116/304
CoughRespiratory, thoracic and mediastinal disorders16/30122/304
HypotensionVascular disorders13/30122/304
DizzinessNervous system disorders19/30114/304
DyspnoeaRespiratory, thoracic and mediastinal disorders19/30115/304

Baseline characteristics

Intent-to-treat (ITT) population included all participants who were randomized to study treatment.

Age, Continuous
Age, Continuous(years)Epoetin HospiraEpogenTotal
Mean55.32 ± 13.05757.35 ± 11.44056.34 ± 12.307
Sex: Female, Male
Sex: Female, Male(Participants)Epoetin HospiraEpogenTotal
Female146131277
Male160175335
09

Study locations

85 sites
  • Montgomery Kidney Specialists
    Montgomery, Alabama 36106, United States
  • Southwest Clinical Research Institute, LLC
    Tempe, Arizona 85284, United States
  • Lakhi M. Sakhrani, MD A Medical Coporation
    Alhambra, California 91801, United States
  • North America Research Institute
    Azusa, California 91702, United States
  • DaVita Dialysis Center-Bakersfield Dialysis Center
    Bakersfield, California 93309, United States
  • Ong, Rubin, Shahmir A Medical Corp DBA: Solano Kidney Care
    Fairfield, California 94533, United States
  • A Medical Corporation
    Glendale, California 91204, United States
  • Renal Consultants Medical Group
    Granada Hills, California 91344, United States
  • La Puente Dialysis Center
    La Puente, California 91744, United States
  • Advanced Medical Research, LLC
    Lakewood, California 90712, United States
  • DaVita Bixby Knolls Dialysis
    Long Beach, California 90807, United States
  • Bayview Nephrology, Inc
    Long Beach, California 90813, United States
  • Academic Medical Research Institute
    Los Angeles, California 90022, United States
  • Desert Nephrology Medical Group
    Modesto, California 95350, United States
  • La Jolla Clinical Research, Inc.
    National City, California 91950, United States
  • Valley Renal Medical Group
    Northridge, California 91324, United States
  • Ontario Dialysis Inc
    Ontario, California 91762, United States
  • Discovery medical Research Group, Inc.
    Porterville, California 93257, United States
  • Nephrology Educational Services and Research, Inc
    Tarzana, California 91356, United States
  • Queen Dialysis Center
    West Covina, California 91790, United States
  • American Institute of Research
    Whittier, California 90603, United States
  • Mark C. Lee, Inc. Santa Fe Springs Dialysis
    Whittier, California 90606, United States
  • North Valley Nephrology
    Yuba City, California 95991, United States
  • Nephrology and Hypertension Associates
    Middlebury, Connecticut 06762, United States
  • South Florida Nephrology, Inc.
    Coral Springs, Florida 33071, United States
  • South Florida Research Institute
    Lauderdale Lakes, Florida 33313, United States
  • San Marcus Research Clinic, Inc
    Miami, Florida 33015, United States
  • Nephrology Associates of South Miami
    Miami, Florida 33173, United States
  • ARA Naples South Dialysis Center
    Naples, Florida 34112-6703, United States
  • ARA- Naples Dialysis Center, LLC
    Naples, Florida 34119, United States
  • Innovative Medical Research of South Florida, Inc.
    North Miami Beah, Florida 33169, United States
  • Discovery Medical Research Group, Inc.
    Ocala, Florida 34471, United States
  • Central Florida Kidney Centers
    Orlando, Florida 32801-3621, United States
  • Renal Physicians of Georgia, PC
    Dublin, Georgia 31021, United States
  • Boise Kidney & Hypertension Institute, PLLC
    Meridian, Idaho 83642, United States
  • Research by Design, LLC
    Evergreen Park, Illinois 60805, United States
  • North Suburban Nephrology, LLC
    Gurnee, Illinois 60031, United States
  • Nephrology Specialists, PC
    Merrillville, Indiana 46410, United States
  • Westbank Nephrology Associates
    Marrero, Louisiana 70072, United States
  • Internal Medicine Specialists
    New Orleans, Louisiana 70115, United States
  • Northwest Louisiana Nephrology
    Shreveport, Louisiana 71101, United States
  • DaVita Dialysis Centers
    Clinton Township, Michigan 48038, United States
  • St. Clair Specialty Physicians, P.C.
    Detroit, Michigan 48236, United States
  • South Mississippi Medical Research, PLLC
    Gulfport, Mississippi 39501, United States
  • Chromalloy American Kidney Center
    Saint Louis, Missouri 63110, United States
  • Kidney Specialists of Southern Nevada
    Las Vegas, Nevada 89106, United States
  • Hypertension & Nephrology Associates
    Eatontown, New Jersey 07724, United States
  • Brookdale Physician Dialysis Associates
    Brooklyn, New York 11212, United States
  • Lower Manhattan Dialysis Center
    New York, New York 10016, United States
  • Mountain Kidney and Hypertension Associates, PA
    Asheville, North Carolina 28801, United States
  • East Carolina University, ECU School of Medicine, Department of Internal Medicine
    Greenville, North Carolina 27834, United States
  • Eastern Nephrology Associates, PLLC
    New Bern, North Carolina 28562, United States
  • Brookview Hills Research Associates, LLC
    Winston-Salem, North Carolina 27103, United States
  • Cincinnati VA Medical Center
    Cincinnati, Ohio 45220, United States
  • HNC Dialysis Ltd.
    Columbus, Ohio 43215, United States
  • Bayview Nephrology, Inc
    Erie, Pennsylvania 16507, United States
  • DaVita-Erie Dialysis Center
    Erie, Pennsylvania 16507, United States
  • UPMC Hamot Clinical Trials Department
    Erie, Pennsylvania 16507, United States
  • Franklin Dialysis Center
    Philadelphia, Pennsylvania 19106, United States
  • Delaware Valley Nephrology and Hypertension Associates, PC
    Philadelphia, Pennsylvania 19118, United States
  • Nephrology and Internal Medicine of Anderson
    Anderson, South Carolina 29621, United States
  • Columbia Nephrology Associates, P.A.
    Columbia, South Carolina 29203, United States
  • Columbia Nephrology Associates, PA
    Columbia, South Carolina 29203, United States
  • Palmetto Nephrology, PA
    Orangeburg, South Carolina 29118, United States
  • South Carolina Nephrology and Hypertension Center, Inc.
    Orangeburg, South Carolina 29118, United States
  • Desert Nephrology Medical Group
    Sumter, South Carolina 29150, United States
  • Southeast Renal Research Institute
    Chattanooga, Tennessee 37404, United States
  • South Arlington Dialysis Center
    Arlington, Texas 76015, United States
  • Texas Renal Care
    Greenville, Texas 75402, United States
  • Med Center Dialysis
    Houston, Texas 77004, United States
  • Meyerland Dialysis
    Houston, Texas 77035, United States
  • Millenium Clinical Research, Inc.
    Houston, Texas 77054-11801, United States
  • Millennium Clinical Research, Inc.
    Houston, Texas 77054-11801, United States
  • Research Across America
    Houston, Texas 77054, United States
  • Southwest Houston Dialysis
    Houston, Texas 77071, United States
  • Southwest Houston Research, Ltd.
    Houston, Texas 77099, United States
  • Texas Tech University Health Sciences Center
    Lubbock, Texas 79430, United States
  • Private practice of Roberto Mangoo-Karim MD
    McAllen, Texas 78503, United States
  • Missouri City Dialysis
    Missouri City, Texas 77489, United States
  • San Antonio Kidney Disease Center Physicians Group, P.L.L.C.
    San Antonio, Texas 78229, United States
  • DaVita Dialysis Center-Floyd Curl Dialysis
    San Antonio, Texas 78240, United States
  • Clinical Research and Consulting Center, LLC
    Fairfax, Virginia 22030, United States
  • Peninsula Kidney Associates
    Hampton, Virginia 23666, United States
  • Internal Medicine Kidney and Hypertension Center
    Norfolk, Virginia 23502, United States
  • Consolidated Medical Plaza
    Caguas, 00725, Puerto Rico
10

References and documents

Publications

  • Wish JB, Rocha MG, Martin NE, Reyes CRD, Fishbane S, Smith MT, Nassar G. Long-term Safety of Epoetin Alfa-epbx for the Treatment of Anemia in ESKD: Pooled Analyses of Randomized and Open-label Studies. Kidney Med. 2019 Aug 28;1(5):271-280. doi: 10.1016/j.xkme.2019.06.009. eCollection 2019 Sep-Oct. PubMed 32734207 ↗
11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2012 to primary completion in Feb 2014, 24 months.

Results were first posted in Jul 2018, 4 years 5 months after primary completion. A results delay was requested in Feb 2015.

Of 42 industry-sponsored phase 3 interventional studies under Kidney Failure, Chronic, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 40. This study's 24 months is below that.

Counting every sponsor, half of 66 studies reached it within 32 months; a quarter within 21 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2011
First posted
Nov 17, 2011
StartActual
Jan 31, 2012
Primary completionActual
Feb 11, 2014
CompletionActual
Feb 11, 2014
Results delay requested
Feb 23, 2015
Results first posted
Jul 13, 2018
Last update
Sep 10, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT01473407
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 17, 2011
Start date
Jan 31, 2012
Primary completion
Feb 11, 2014
Completion
Feb 11, 2014
Results posted
Jul 13, 2018
Last update
Sep 10, 2018

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epoetin Alfa

Start the discussion